The U.S. Government has released the "National Action Plan for Combating MDR-TB" in order to address the leading infectious cause of death in the world. The goals of the five-year National Action Plan (NAP) are to:
TB CARE II core
The Union World Conference on Lung Health continues to be the largest gathering of clinicians and public health professionals, program managers, policymakers, researchers, and advocates working to end suffering caused by TB and other lung diseases. The 48th annual conference, held in Guadalajara, Mexico on October 11-14, 2017, continued this tradition with fruitful discussions, research presentations, and other cutting-edge developments.
Isoniazid Preventative Therapy (IPT) is a highly effective tuberculosis (TB) prevention method for people living with HIV, with a 33-64% reduction in TB in HIV+ patients who completed IPT. This benefit is enhanced to an 80-95% reduction when IPT is combined with proper anti-retroviral therapy (ART).
The “Best Practices in DR-TB Community Care: Development of National Community-Based DR-TB Care Plans” workshop was held in Pretoria, South Africa on the 11 - 13 September 2017, as part of the USAID-funded TB CARE II project, managed by URC. This workshop presented current best practices in drug-resistant tuberculosis (DR-TB) community care and support, with the goal of developing national roll-out plans for each of the 10 National Action Plan priority countries.
The FAST strategy is mainly implemented at specialized and general hospitals with TB units. With support from the USAID TB CARE II Project, the Vietnam NTP developed the “Guideline for FAST strategy implementation”. According to the Guideline, implementing facilities should immediately order GeneXpert MTB/RIF tests for eligible patients including: Pulmonary TB patients AFB(+), presumptive drug-resistant TB patients, presumptive TB among HIV positive people, children with presumptive TB or TB meningitis.
Tumpa, a 14 year old high school student, was diagnosed with TB on March 27, 2011. Although she started taking TB medication the day after, she experienced treatment failure after three months of treatment and was diagnosed with Multi Drug Resistance Tuberculosis (MDR-TB). With her new diagnosis, Tumpa started to take her medication for MDR-TB in August of that year. However, after completing 16 months of treatment, her sputum culture and follow up result remained positive. She was then diagnosed with extensively drug-resistant TB (XDR-TB) in November 2012.
Watch the video in the link below for an overview on TB CARE II through out the past six years.
TB disease occurs most often within the context of economic and social vulnerabilities, and patients receiving TB treatment frequently